{ "schemaVersion": "2.1", "datasetVersion": "2026-09-11.1", "generatedAt": "2026-09-11", "reviewStatus": "Editorial source review is complete. This edition has not been independently medically reviewed.", "editorialBoundary": "Source-checked educational summaries. Topics require evidence and editorial review. This dataset is not a personal treatment plan.", "citation": "When you cite a record, include The Peptide Field, its canonicalPath, this dataset version, and every source used for the claim.", "reuse": "This endpoint grants no additional reuse license. Keep the verdict, scope, evidence basis, review date, and source links together. Do not present a record as medical advice or medical review.", "changeLogPath": "/corrections#correction-ledger", "contactPath": "/corrections", "dataset": "peptide-evidence-checker-record", "canonicalPath": "/peptides/tesamorelin", "canonicalUrl": "https://thepeptidefield.com/peptides/tesamorelin", "record": { "slug": "tesamorelin", "name": "Tesamorelin", "aliases": [ "Egrifta SV", "Egrifta WR", "TH9507", "GHRF analogue" ], "className": "Growth hormone-releasing factor analogue", "family": "Growth signaling", "sequenceLabel": "44 amino acids · stabilized GHRF analogue", "tier": "Established", "evidenceContext": "Approved human outcomes", "statusLine": "An FDA-approved product exists for a narrow indication", "productContext": "The two approved products are not interchangeable. Egrifta SV and Egrifta WR are approved, non-substitutable formulations with product-specific labeling. Tesamorelin sold or compounded outside those products is not automatically equivalent.", "approvedProducts": [ "Egrifta SV", "Egrifta WR" ], "productRecords": [ { "name": "Egrifta SV", "formulation": "2 mg single-dose vial", "route": "Subcutaneous", "indicationScope": "Reduction of excess abdominal fat in adults with HIV and lipodystrophy; not indicated for weight-loss management.", "labelUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022505s018lbl.pdf", "labelRevision": "2024 label" }, { "name": "Egrifta WR", "formulation": "11.6 mg single-patient-use multidose vial", "route": "Subcutaneous", "indicationScope": "Reduction of excess abdominal fat in adults with HIV and lipodystrophy; not indicated for weight-loss management.", "labelUrl": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf", "labelRevision": "March 2025" } ], "indications": [ "Reduction of excess abdominal fat in adults with HIV and lipodystrophy" ], "profile": { "humanOutcomes": { "level": "Strong", "note": "Phase 3 trials support visceral-adipose-tissue reduction in the labeled HIV population." }, "humanPharmacology": { "level": "Strong", "note": "The approved label characterizes IGF-1 response, exposure, and product-specific use." }, "safetyKnowledge": { "level": "Strong", "note": "The label describes neoplasm, glucose, fluid-retention, hypersensitivity, and other risks." }, "productCertainty": { "level": "Strong", "note": "High for authentic Egrifta SV; no automatic transfer to other formulations." } }, "oneLine": "An approved medicine for one specific HIV-related body-composition outcome. It is not a general weight-loss or anti-aging medicine.", "reviewedAt": "August 1, 2026", "reviewedAtISO": "2026-08-01", "reviewHistory": [ { "date": "2026-08-01", "note": "Revalidated the current Egrifta WR indication and weight-loss limitation against FDA labeling, and confirmed tesamorelin remains named on the 2026 WADA Prohibited List." }, { "date": "2026-07-23", "note": "Updated for Egrifta SV and Egrifta WR product identity, non-substitutability, phase 3 outcomes, and the 2026 WADA list." } ], "whatItIs": "Tesamorelin is a changed version of a body signal that releases growth hormone. The approved product has a narrow labeled group of people and outcome.", "whatWeKnow": "Controlled trials in adults with HIV-associated abdominal fat accumulation found less visceral fat, which is fat around internal organs. The Egrifta SV and Egrifta WR labels say the products are not indicated for weight-loss management and that long-term cardiovascular safety has not been established. Their formulations are not substitutable.", "whatWeDoNotKnow": "These results do not establish general fat loss, muscle gain, anti-aging benefit, athletic recovery, or equivalent outcomes from compounded products.", "antiDoping": "Tesamorelin appears on the 2026 World Anti-Doping Agency Prohibited List within the S2 peptide-hormone and growth-factor category as a growth-hormone-releasing hormone analogue.", "antiDopingReview": { "status": "Prohibited", "detail": "Tesamorelin is named as a prohibited growth-hormone-releasing hormone analogue on the 2026 WADA Prohibited List and is prohibited at all times for covered athletes.", "sourceUrl": "https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list", "reviewedAtISO": "2026-08-01" }, "safetyBoundary": "This prescription drug has benefits for a specific group and important monitoring requirements. No dosing, cycling, stacking, or performance-use guidance is provided.", "relatedSlugs": [ "cjc-1295", "sermorelin", "ipamorelin" ], "claims": [ { "claim": "“Tesamorelin reduces visceral fat in adults with HIV-associated lipodystrophy.”", "verdict": "Supported with scope", "explanation": "Phase 3 trials and the product label support this outcome in the labeled population.", "category": "Body composition", "evidenceBasis": "Randomized human outcomes", "scope": "Adults with HIV and excess abdominal fat meeting the trial and label criteria.", "sourceUrls": [ "https://pubmed.ncbi.nlm.nih.gov/20101189/", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022505s018lbl.pdf", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf" ] }, { "claim": "“Tesamorelin is an approved general weight-loss drug.”", "verdict": "Misleading", "explanation": "The label specifically says it is not indicated for weight-loss management.", "category": "Approval and status", "evidenceBasis": "Regulatory or product record", "scope": "The current Egrifta SV and Egrifta WR labels.", "sourceUrls": [ "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022505s018lbl.pdf", "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf" ] }, { "claim": "“Tesamorelin is permitted for competitive athletes.”", "verdict": "Misleading", "explanation": "The 2026 WADA Prohibited List names tesamorelin in the S2 peptide-hormone and growth-factor category, which is prohibited at all times for covered athletes.", "category": "Performance and recovery", "evidenceBasis": "Regulatory or product record", "scope": "Sport governed by the World Anti-Doping Code.", "sourceUrls": [ "https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list" ] } ], "sources": [ { "label": "EGRIFTA SV (tesamorelin) prescribing information", "publisher": "U.S. Food and Drug Administration", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022505s018lbl.pdf", "kind": "Drug label", "year": 2024, "accessedAt": "2026-07-23" }, { "label": "EGRIFTA WR (tesamorelin) prescribing information", "publisher": "U.S. Food and Drug Administration", "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022505s020lbl.pdf", "kind": "Drug label", "year": 2025, "accessedAt": "2026-07-23" }, { "label": "Tesamorelin in HIV-associated abdominal fat accumulation", "publisher": "PubMed · Journal of Acquired Immune Deficiency Syndromes", "url": "https://pubmed.ncbi.nlm.nih.gov/20101189/", "kind": "Randomized trial", "year": 2010, "accessedAt": "2026-07-23" }, { "label": "2026 Prohibited List", "publisher": "World Anti-Doping Agency", "url": "https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list", "kind": "Anti-doping", "year": 2026, "accessedAt": "2026-07-23" } ] } }